c-Kit (Mast/stem cell growth factor receptor, SCFR or CD117) is a proteinthat in humans is encoded by the KIT gene.An essential cell surface marker for identifying specific kinds of hematopoietic (blood) progenitors in the bone marrow is called c-Kit (CD117). In addition to other cell types, hematopoietic stem cells express the cytokine receptor c-Kit on their surface. Some types of cancer may be linked to altered forms of this receptor. Stem cell factor is bound by the type III receptor tyrosine kinase known as c-Kit. To activate its intrinsic tyrosine kinase activity, c-Kit forms an adimer with stem cell factor (SCF). This adimer then phosphorylates and activates signal transduction molecules that spread the signal throughout the cell. Cell survival, division, and proliferation are affected by c-Kit signaling.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V77254 | Anti-Mouse CD117 Antibody | Anti-Mouse CD117 Antibody is an IgG2b antibody inhibitor against mouse CD117. | |
|
V2886 | Avapritinib | 1703793-34-3 | Avapritinib (formerly known as BLU-285; trade name Ayvakit) is an oral, potent and selective small molecule inhibitor of PDGFRα D842V and KIT Exon 17 mutants (IC50=0.5 nM) with anticancer activity. |
|
V3474 | AZD3229 | 2248003-60-1 | AZD3229 (AZD-3229) is a novel, potent, pan-KIT mutantinhibitor with anticancer activity. |
|
V4154 | AZD3229 Tosylate | 2248003-71-4 | AZD3229 Tosylate, the tosylate salt ofAZD-3229,is a novel, potent, pan-KIT mutantinhibitor with antitumor activity. |
|
V69293 | Barzolvolimab (CDX 0159) | 2438203-51-9 | Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody (mAb). |
|
V69291 | Bezuclastinib (CGT9486; PLX 9486) | 1616385-51-3 | Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V, 0.0001 |
|
V0631 | Dasatinib Monohydrate (BMS354825; Sprycel) | 863127-77-9 | Dasatinib (formerly BMS-354825; trade name Sprycel), an approved anticancer drug, is an orally bioavailable and multi-targeted kinase inhibitorof Abl, Src and c-Kit with potential anticancer activity. |
|
V3757 | DCC-2618 HCl | Ripretinib HCl (DCC2618; DCC-2618; Qinlock), the hydrochloride salt of DCC-2618, is an orally bioactive pan KIT and PDGFRA inhibitor approved in 2020 for the treatment of adults with advanced gastrointestinal stromal tumor. | |
|
V69295 | Elenestinib (BLU-263) | 2505078-08-8 | Elenestinib (BLU-263) is a potent orally bioactive tyrosine kinase inhibitor. |
|
V69296 | Elenestinib phosphate (BLU-263 phosphate) | 2832013-93-9 | Elenestinib phosphate (BLU-263 phosphate) is a potent orally bioactive tyrosine kinase inhibitor. |
|
V0572 | Imatinib Mesylate (STI571; Gleevec; Glivec) | 220127-57-1 | Imatinib Mesylate (also known as STI571 mesylate; trade names: Gleevec or Glivec), the mesylate salt of imatinib, is an orally bioavailable,potent,multi-kinase inhibitor of v-Abl, c-Kit and PDGFR with potential antitumor activity. |
|
V22674 | ISCK03 | 945526-43-2 | ISCK03 is a potent c-kit inhibitor. |
|
V69290 | Labuxtinib | 1426449-01-5 | Labuxtinib is a c-kit tyrosine kinase inhibitor (TKI). |
|
V0630 | Pexidartinib (PLX3397; Turalio; CML261; FP113) | 1029044-16-3 | Pexidartinib (formerly PLX-3397; CML-261;FP-113; trade name Turalio) is an orally bioavailable and multi-targeted RTK (receptor tyrosine kinase) inhibitor of CSF-1R, Kit, and Flt3 with potential antineoplastic activity. |
|
V13471 | Quarfloxin | 865311-47-3 | Quarfloxin (Quarfloxacin; CX-3543) is a novel and potent fluoroquinolone analoguewith anticancer activity. |
|
V15392 | SU14813 | 627908-92-3 | SU14813 is a novel, orally bioavailable, multi-targeted tyrosine kinase inhibitor (TKI) withIC50s of 50, 2, 4, 15 nM forVEGFR2,VEGFR1,PDGFRβandKIT, respectively. |
|
V69294 | VEGFR-IN-1 | 269390-69-4 | VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor (antagonist) with IC50 of 0.02, 0.18, 0.24, 7.3, and 7 for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
